Dendreon Corporation is a biotechnology company developing targeted therapies for cancer. Dendreon currently has three vaccine candidates in clinical trials -- Provenge, for the treatment of prostate cancer; Mylovenge(TM), for the treatment of multiple myeloma; and APC8024, for the treatment of breast, ovarian and colon cancers. Dendreon\'s product pipeline also includes monoclonal antibodies and a pathway to small molecules. Dendreon has established important alliances with industry leaders Genentech, Johnson & Johnson Pharmaceutical Research & Development and Kirin Brewery Co., Ltd.